Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®

Launched by UNIVERSITY HOSPITAL, LIMOGES · Mar 25, 2025

Keywords

ClinConnect Summary

The "Scanvir" clinical trial is studying a new approach to screen and treat viral hepatitis B, C, and HIV among people who use drugs and other vulnerable groups. The goal is to make it easier for these populations to get tested and receive care, especially in places like addiction care centers where they feel comfortable. This trial will help researchers understand how well this "test, treat, and cure" strategy works and whether it can be successfully used in different communities.

To participate in this trial, you need to be at least 18 years old and frequent an unconventional support structure, like addiction care centers. You should also be open to participating in research. If you join the study, you can expect to be tested for these viruses during special screening days, with the hope of improving your health outcomes. It's important to know that this study is not yet recruiting participants, so you would need to wait for it to start if you're interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult 18 and over
• • Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
• • Patient not opposed to research
• Exclusion Criteria:
• • Age under 18
• • Patient opposed to research